Sanofi Introduces New Long-Acting Insulin Drug in India

The Central Drugs Standard Control Organization has granted Sanofi (India) marketing authorization for their diabetes medicine Soliqua (in pre-filled pen). (CDSCO). Soliqua is suggested as a medication to improve glycemic control in persons with obesity and type 2 diabetes who are not well controlled on oral or injectable treatments.

It is available in once-daily pre-filled pens with fixed-ratio combinations of 10-40 and 30-60 of insulin glargine and lixisenatide. "With approximately 74 million Indians aged 20 to 79 living with diabetes, healthcare professionals require more treatment options to tailor diabetes care to them."

"Soliqua is the most recent addition to our comprehensive diabetes portfolio (OADs and insulins) indicated for people with obesity who have poorly controlled diabetes," said Cyrus Aibara, head of Sanofi's Diabetes Business Unit. (India) "The global Solimix study, which included Indian patients, demonstrated that once daily Soliqua provides a weight benefit and less hypoglycemia than twice daily premixed insulin, making it a valuable option for endocrinologists," said Dr. Shalini Menon, Country Medical Lead, Sanofi. (India).